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Abstract
In this study, the neuroprotective effect of various nicotinic alpha7
acetylcholine receptor agonists in an in-vivo model of glaucoma using adult
Long Evans rats was analyzed. Glaucoma-like conditions were induced in
the eyes of Long Evans rats after injection of hypertonic saline into episcleral
veins to create scar tissue and increase the animal’s intraocular pressure. This
procedure produced significant loss of retinal ganglion cells within one month
and was associated with an increase of intraocular pressure. Using this model
system, various alpha7 nicotinic acetylcholine receptor (α7 nAChR) agonists
were applied at different doses as eye drops to the right eye of adult Long Evans
rats while the left eye was left as an internal control. The α7 nAChR agonists
used in this study prevented loss of RGCs in a dose dependent manner after
the procedure to induce glaucoma-like conditions. PHA-543613 and PNU282987 provided the largest degree of RGC survival after inducing glaucomalike conditions, followed by nicotine, SEN 12333, tropisetron, 3-Bromocytisine
and DMAB. To provide evidence that neuroprotection of RGCs was mediated
through activation of α7 nAChR, in some studies different concentrations of the
α7 nAChR antagonist, MLA, was intravitreally injected into experimentally treated
eyes before initiation of eye drops and the procedure to induce glaucoma-like
conditions. In the presence of MLA, RGC neuroprotection was blocked. Results
from these studies suggest that selective α7 nAChR agonists may be used in
future therapeutic treatments for glaucoma or other CNS diseases associated
with α7 nAChRs.
Keywords: Alpha7 nicotinic acetylcholine receptors; Glaucoma; Retina;
Retinal ganglion cells; Acetylcholine; Nicotinic agonists

Abbreviations
ACh: Acetylcholine; α7 nAChRs: Alpha7 Nicotinic Acetylcholine
Receptors; CO2: Carbon Dioxide; DMAB: 4-[(5,6-Dihydro[2,3’bipyridin]-3(4H)-ylidene)methyl]-N,N-dimethylbenzenamine
dihydrochloride; DMSO: Dimethyl Sulfoxide; hERG: human
Ether-a-go-go Related Gene; IACUC: Institutional Animal Care
and Use Committee; IOP: Intraocular Pressure; KAX: Ketamine,
Acepromazine and Xylaxine cocktail; LC MS/MS: Liquid
Chromatography, Mass Spectroscopy, Mass Spectroscopy; ONH:
Optic Nerve Head; PBS: Phosphate Buffer; RGCs: Retinal Ganglion
Cells; NaCl: Sodium Chloride

Introduction
Glaucoma is one of the leading causes of blindness worldwide [13]. It is a neurodegenerative disorder characterized by a progressive
optic neuropathy, cupping of the optic disk, the death of RGCs and
degeneration of axons in the optic nerve [4,5]. The primary risk factor
associated with glaucoma is an increase in intraocular pressure,
which has been linked to apoptosis of Retinal Ganglion Cells (RGCs)
[6-8]. Recently, a great deal of research has explored the agents and
mechanisms that provide neuroprotection against neurodegenerative
conditions. Activation of alpha7 nicotinic acetylcholine receptors (α7
nAChRs) in the brain have been linked to neuroprotection against
several neurodegenerative diseases [9,10]. There is strong evidence

J Ophthalmol & Vis Sci - Volume 1 Issue 1 - 2016
ISSN: 2573-8593 | www.austinpublishinggroup.com
Linn et al. © All rights are reserved

that α7 nAChRs are neuroprotective, reducing β-amyloid induced
toxicity in Alzheimer’s disease [11,12] and that the α7 nAChRs plays
a role in the pathophysiology of schizophrenia [13,14]. In the retina,
RGCs contain α7 nAChRs [15-17] and receive cholinergic input from
a well-described population of starburst amacrine cells [18,19]. They
are the only source of ACh in the vertebrate retina. Previous studies
have demonstrated that intravitreal injections or eye drop application
of the α7 nAChR agonist, PNU-282987, in an in vivo rat model,
prevented the loss of RGCs typically associated with a procedure to
induce glaucoma-like conditions [20,21].
Binding studies in rat chimera cells using PNU-282987 have
demonstrated that PNU-282987 is a potent specific agonist for α7
nAChRs [22]. These studies demonstrated that Methyllycaconitine
(MLA), a specific α7 nAChR antagonist, preferentially bound to
α7 nAChRs when both PNU-282987 and MLA were present. In
electrophysiology studies using rat hippocampal neurons, PNU282987 evoked a rapidly desensitizing inward whole-cell current
associated with the opening of the α7 nAChR channel. This current
was eliminated if MLA was introduced before PNU-282987 [22].
Although PNU-282987 has been used in animal schizophrenia
models, it has not been found to be suitable for systemic use in
humans because of excessive inhibition of a hERG anti target in the
heart [23]. As a result, other α7 nAChR agonists were investigated
to determine their neuroprotective effect following topical delivery
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in a rat glaucoma model. Comparisons between the neuroprotective
effect of PNU-282987 and the other α7 nAChR agents are discussed.
The results from these studies support the hypothesis that α7 nAChR
agonists may have a role in the future as a therapeutic intervention
for glaucoma.

proparacaine hydrochloride before using the Tono-Pen. Rats were
loosely held in the experimenter’s hand during this procedure. IOP
measurements were obtained each day for 1 week before hypertonic
injections and 5 times each week after hypertonic injections until the
rats were sacrificed [20].

Materials and Methods

Eye treatments

Animals
Both male and female adult Long Evans rats were used in this
study. Rats were used at 3 months of age. Out bred Long Evans rats
were chosen because of their docile nature, pigmented eyes, the lack
of genetic defects that are associated with other inbred rat species and
for consistency with studies already completed [20,21]. All animals
were cared for in accordance with the approved guidelines of the
Institutional Animal Care and Use Committee (IACUC) at Western
Michigan University.
Anesthesia
To anesthetize Long Evans rats, animals were injected
intraperitoneally with 1.0 ml/kg KAX standard rat cocktail;
consisting of a solution of 5 ml of ketamine (100 mg/ml), 2.5 ml of
xylazine (20 mg/ml), and 1 ml of acepromazine (10 mg/ml) in 3 ml
sterile water. KAX was injected prior to hypertonic saline injections
to induce glaucoma and prior to intravitreal injections (if utilized in
the experiment). To ensure complete anesthesia, a lack of tail and
toe pinch reflex were needed before proceeding with procedures.
After the procedures were completed, rats were placed on a warm
circulating water pad and watched until they were fully awake and
functioning normally before being returned to the animal colony.
Procedure to induce glaucoma
To induce glaucoma, rats were anesthetized with an intraperitoneal
injection of KAX and two drops of pilocarpine were added to the
right eye of each rat to prevent the blinking reflex. After applying
betadine solution around the eye, a hemostat was used to pinch the
skin surrounding the eye to bulge the eye from the eye socket and
reveal the episcleral vein for hypertonic saline injection. The right eye
in each animal was used for procedural manipulation while the left
eye served as an untreated internal control for each experiment unless
noted otherwise. Under a dissection microscope, the episcleral vein
of the right eye was injected with 50 µL of 2M NaCl using a micro
needle assembly [20]. Injection of 2M NaCl caused blanching of the
vein, which ensured a successful injection. Observation of a blanched
vein correlated to a significant loss of RGCs one month following the
procedure [20]. Following the injection, a small amount of antibiotic
ointment was applied over the injection site and where the hemostat
pinched the skin around the eye. This procedure was modified from
the procedure originally developed by Morrison et al. [24]. In sham
procedure studies, injections were made with PBS instead of ACh
agonists.
IOP measurements using Tonopen
IOP measurements were obtained before hypertonic injections
to obtain a baseline and after hypertonic injections into the
episcleral veins to measure any increase of IOP. IOP measurements
were obtained from awake behaving rats using the Tono-Pen XL
tonometer (Mentor, Norwell MA) according to instructions outlined
by Morrison et al. [24]. Rat eyes were anesthetized with 1 drop of 0.5%
Submit your Manuscript | www.austinpublishinggroup.com

Previous in vivo studies on adult Long Evans rats have shown
that the α7 nAChR specific agonist, PNU-282987, prevented the
loss of RGCs typically associated with inducing glaucoma-like
conditions when applied as eye drops [21]. Other studies have also
demonstrated that pharmacological agents can reach the retina if the
agents are dissolved in appropriate vehicles [25-27]. In this study,
the neuroprotective effect of the following commercially available
α7 nAChR agonists were examined, including PHA-543613, PNU282987, nicotine, SEN 12333, tropisetron, 3-bromocytisine and
DMAB. Three different concentrations of each agent were used
for dose-response studies. The concentrations of agents used were
based on previously obtained preliminary results. ACh agonists were
dissolved in Dimethyl Sulfoxide (DMSO) to make a stock solution
and then diluted in PBS and sterilized using syringe filters. 30 µl eye
drops were applied for three days to the bulbar conjunctiva of the
eye before the injection of hypertonic solution to induce glaucomalike conditions and for one month following the procedure [20,21].
Eye drops were applied twice a day based on previous LC MS/MS
studies that demonstrated evidence of PNU-282987 in the retina up
to 12 hours after treatment [20]. Between 4 and 20 animals were used
for each experiment. The left eye in each animal was untreated and
served as an internal control to compare against the experimentally
treated right eye. After one month, animals were sacrificed by C02
asphyxiation and retinas were removed for RGC labeling. Vehicle
control experiments were performed concurrently using only PBS eye
drops (N=4), or eye drops containing up to 1% DMSO (N=4).
To support the hypothesis that the ACh agonists act through α7
nAChRs, experiments were performed using a specific α7 nAChR
antagonist, MLA. In these experiments, 5 µL of various concentrations
of the α7 nAChR specific antagonist, MLA (0, 1, 10, 100nM) (N=4 for
each concentration),was injected directly into the vitreal chamber of
the right eye using a Hamilton syringe 1 hour before initiation of eye
drop treatments and before the procedure to induce glaucoma-like
conditions.
Tissue preparation and analysis
One month following the hypertonic saline injection, rats were
euthanized using CO2 asphyxiation. Both eyes were subsequently
removed and processed [20]. After removal of the cornea, lens and
vitreous humor, the whole retina was peeled away from the back of the
eye cup. Care was taken to remove the retina in one piece to maintain
geographical orientation and landmarks. Once the whole retinas were
removed, four short evenly spaced slits were made around the retina’s
periphery that allowed the retinas to be flattened. The retina was then
pinned out flat onto sylgard plates using cactus needles and fixed
in 4% paraformaldehyde for 24 hours at 4oC. The next day, retinas
were rinsed, blocked and permeabilized with 2% bovine serum
and 1% triton X-100 (Sigma) for two hours at room temperature.
Retinas were then immunostained with antibodies against Thy 1.1
or double-labeled with antibodies against Thy 1.1 and Brn3a. AntiJ Ophthalmol & Vis Sci 1(1): id1003 (2016) - Page - 02
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Thy 1.1 (mouse anti-rat, BD Biosciences) is a monoclonal antibody
against glycoproteins found exclusively on the plasma membrane
of RGCs in the retina [28]. Anti-Brn3a is an antibody that labels the
transcription factor found in RGCs [29]. For single labeling of RGCs,
the primary antibody, mouse anti-Thy1.1 (1:300, BD Pharmingen)
was added to the flat-mounted retina and incubated overnight on
a rocker, in a humidified chamber at room temperature. 24 hours
later, retinas were rinsed twice in 0.1% Triton X-100 and three times
in PBS. The secondary antibody, Alexa Fluor 594 goat anti-mouse,
was then applied in PBS (1:300, Life technologies) and the retinas
were incubated for 24 hours on a rocker, in a darkened humidified
chamber at room temperature. After incubation in secondary
antibody, the cactus needles were removed and the retinas were
transferred to glass slides and mounted using 50% glycerol and 50%
PBS. When double-labeling RGCs, anti-Thy 1.1 and rabbit anti-Brn3a
(1:300) were used in PBS containing 2% bovine serum. The secondary
antibodies used to visualize double labeled RGCs were Alexa Fluor
594 goat anti-mouse and Alexa Fluor 488 donkey anti-rabbit (1:300,
Life technologies) [20].
Once stained, the number of single or double-labeled RGCs
throughout the RGC layer at specific regions of the retina was
counted from images obtained 4 mm from the Optic Nerve Head
(ONH) using the Z-stack capabilities of a Nikon confocal microscope.
In each retina, 200 µm2 images were obtained from the dorsal retina
containing the highest density of RGCs in the visual streak, the
ventral, nasal and temporal regions of the retina [20]. All images were
obtained 4 mm from the ONH as a previous study demonstrated that
the greatest loss of RGCs occurred in the peripheral retina under
glaucoma conditions [20]. The number of RGCs counted from each
experimentally treated retina were averaged and compared directly
to the number of RGCs obtained from internal control retinas and
normalized by calculating the percent change from each internal
control. Four to twenty different rats were used for each experimental
condition and in control studies to determine if the delivery method
or vehicle had any effect on RGC counts. In other control studies,
experiments were conducted to display specificity of the antibodies
used. In four negative control experiments, retinas were processed
with the primary antibodies omitted, while another four experiments
substituted non-immune mouse immunoglobulin (dilution: 0.1 1.0 µg/ml) for the antibodies. In other experiments, pre absorption
controls were performed where the primary antibody and antigens
were added together before applying to tissue (N=4). No significant
epifluorescence was observed under any of these conditions.
Statistical analysis
For normalized data, statistical analysis was performed using
Kruskall-Wallis non parametric analysis of variance with post
hoc comparisons (Dunn’s test). P-values of < 0.05 represented
significance. Graphs were plotted with Prism GraphPad version 4.0
software (GraphPad Software, Inc., San Diego, CA). All data values
are reported as the mean ± Standard Error (S.E.). Errors bars are
presented one-sided to prevent error bar clutter in dose-response
studies and for consistency.

Results
Glaucoma effects on RGCs
The primary risk factor associated with glaucoma is an increase
Submit your Manuscript | www.austinpublishinggroup.com
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Figure 1: Effects of the glaucoma-inducing procedure on RGC survival.
Figure 1A represents a confocal image obtained 4 mm from the optic nerve
head in a control untreated retina after double-labeling RGCs with antibodies
against Thy 1.1 (red) and Brn3a (green). Thy 1.1 stains glycoproteins found
in the plasma membrane of each RGC (red), while Brn3a is a nuclear
marker for RGCs (green). Figure 1B represents an image obtained from the
experimental eye of the same animal after hypertonic saline was injected into
the episcleral vein to induce glaucoma-like conditions. The image shown was
obtained one month after the procedure and was obtained from the same
retinal location as the image shown from the internal control eye. Arrows
indicate RGCs. The bar graphs in figure 1C represent the average percent
survival of RGCs compared to internal controls under different conditions.
To generate the sham results, PBS was injected into the episcleral veins
instead of hypertonic saline. The star represents significant difference from
the control untreated condition. Error bars represent S.E.

in Intraocular Pressure (IOP) [30-32]. Earlier studies from this lab
using the Tono-Pen XL tonometer (Mentor, Norwell MA) have
demonstrated that injection of hypertonic saline into Long Evans
rat’s episcleral veins significantly increased intraocular pressure
from an average of 13 mm Hg before the procedure to induce
glaucoma to an average of 21 mm Hg within one month afterward
[20]. Corresponding with this increase of intraocular pressure is a
significant loss of RGCs. (Figure 1) illustrates the typical loss of RGCs
that result from 50 µl injection of 2M NaCl into the episcleral vein of
adult anesthetized Long Evans rats. (Figure 1A) is an image obtained
from the left control untreated eye of a flat-mounted retina doublelabeled with antibodies against the glycoprotein, Thy 1.1 and the
RGC nuclear marker, Brn3a. Images were obtained from the nerve
fiber layer and the RGC layer using a Nikon confocal microscope.
The antibody against Thy 1.1clearly labeled the plasma membrane of
RGC bodies (arrows) when secondarily labeled with Alexa Fluor 594.
Anti-Brn3a also labeled RGCs and was found to be co-localized in
cell bodies of the RGC layer that labeled with Thy 1.1. The anti-Brn3a
antibody was secondarily labeled with Alexa Fluor 488. Co-labeled
RGCs occurred 95.5% (+/-3.5; N=5) of the time.
Figure 1B illustrates a confocal retinal image obtained from the
right eye of the same animal; one month after hypertonic saline was
injected into the animal’s episcleral vein. Both images in (Figures
1A & 1B) were obtained from the same geographical location in
the retina, 4 mm from the ONH. As seen in (Figure 1B), there was
significant loss of RGCs after inducing glaucoma-like conditions.
J Ophthalmol & Vis Sci 1(1): id1003 (2016) - Page - 03
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Table 1: Mean IOP measurements. H.I. = hypertonic injection into episcleral
veins. Each value represents average IOP measurements obtained from 4
different animals.
Averaged IOP
Averaged IOP (mm Hg) (experimental eye
Treatment
(mm Hg)
after 1 month)
(left control eye)
H.I.

11.9 +/- 2.1

22.4 +/- 2.2

12.1 +/- 1.8

24.6 +/- 2.1

10.8 +/- 3/1

23.7 +/- 1/8

H.I./ nicotine

12.1 +/- 2.1

24.2 +/- 3.1

H.I./ SEN 12333

12.6 +/- 1/3

23.6 +/- 3/1

H.I./ tropisetron

10.8 +/- 2.1

21.8 +/- 2.8

H.I./
3-bromocytisine

11.7 +/- 1.8

22.2 +/- 1.9

H.I./DMAB

10.9 +/- 2.2

21.6 +/- 2/4

H.I. / PHA543613
H.I./ PNU282987

Figure 2: Neuroprotective effect of α7 nAChR agonists.
The line graphs in figure 2 summarize the dose-response experiments
performed using 7 different α7 nAChR agonists. Each data point represents
the average percent of RGCs normalized to internal control numbers obtained
from the same animal and from the same peripheral retinal location. Each
data point was obtained after the right eye of adult Long Evans rats were
treated with various concentrations of the α7 nAChR agonists as eye drops
after the procedure to induce glaucoma-like conditions was performed. The
data points were curve fit. N’s between 4 and 20 were obtained for each
data point. After one month, animals were euthanized, retinas were removed
and RGCs were labeled with anti-Thy 1.1 antibody to label RGCs. Error bars
represent S.E.

One month after the procedure to induce glaucoma-like conditions,
there was a significant average percent loss of RGCs by 28.1% (+/- 5.2,
N=20) compared to the internal untreated condition (Figure 1C) in
the peripheral retina. In sham studies, sterile PBS was injected into
the rat’s episcleral vein instead of 2M NaCl (Figure 1C). There was no
significant change in RGC counts associated with injection of PBS or
with the procedure of injection by itself.
Neuroprotection of RGCs with α7 nAChR agonists
In this dose-response study, seven commercially available α7
nAChR agonists at three different concentrations were applied as
eye drops to the right eyes of adult Long Evans rats that had the
procedure to induce glaucoma. The left eyes were not treated and
acted as an internal control. One month after the procedure, animals
were sacrificed and RGCs were immunostained with antibodies
against Thy 1.1, quantified, compared to internal controls and
normalized. All α7 nAChR agonists prevented the loss of RGCs in a
dose dependent manner (Figure 2). The greatest significant degree of
neuroprotection occurred when PHA-543613 was applied as eye drop
treatment followed by PNU-282987, nicotine, SEN 12333, tropisetron,
3-bromocytisine and DMAB. Both PHA-543613 and PNU-282987
induced significant RGC neuroprotection when applied as 10 µM.
In addition, eye drops containing 100 or 1000 µM PHA-543613
and PNU-282987 provided significantly greater neuroprotection of
RGCs compared to any other agent tested. Lastly, when eye drop
concentrations of 1 mM were applied, both PHA-543613 and PNU282987 eliminated the loss of RGCs associated with the procedure to
induce glaucoma-like conditions by an average of 118% +/-10 and
110% +/- 5 respectively. This represented a significant increase of
Submit your Manuscript | www.austinpublishinggroup.com

Figure 3: Neuroprotective effect of PNU-282987 is mediated through α7
nAChRs.
Figure 3A represents a typical confocal image obtained from the peripheral
retina in a control untreated adult Long Evans rat. RGCs were immunostained
with anti-Thy 1.1. The left eye of the same animal was treated with 1 mM
PNU-282987 after the procedure to induce glaucoma-like conditions. Figure
3B was obtained from the same retinal location as figure 3A. The typical loss
of RGCs due to the procedure did not occur. The confocal images shown in
3C and D were obtained from another adult Long Evans rat. Retinal images
from both eyes of this animal are shown and both eyes had the procedure
to induce glaucoma-like conditions. However, while the left eye (3C) had
no treatment, the right eye (Figure 3D) had an intravitreal injection of MLA
before the procedure to induce glaucoma-like conditions and subsequent
treatment with PNU-282987. In the presence of MLA, PNU-282987 failed
to provide neuroprotection. Arrows represent RGC bodies, double arrows
represent Thy 1.1 labeled axon fascicles and arrow heads represent axons
that defasciculate off the main axon bundles as RGCs are lost.

RGCs compared to internal controls (see discussion). In control eye
drop studies, application of PBS or PBS in DMSO up to 1% had no
significant effect of RGC survival.
Previous studies from this lab using the Tono-Pen XL tonometer
(Mentor, Norwell MA) have demonstrated that injection of
hypertonic saline into rat episcleral veins significantly increased
intraocular pressure [20]. In this current study, the procedure to
J Ophthalmol & Vis Sci 1(1): id1003 (2016) - Page - 04

Linn CL

Austin Publishing Group

induce glaucoma-like conditions in adult Long Evans rats significantly
increased the average IOP measurement from control untreated levels
of 12.8 (+/- 0.5) to 24.3 (+/0 1.2) (Table 1). Topical application (1
mM) of the seven α7 nAChR agonists used in this study for 1 month
had no significant effect on the change of IOP measurements (Table
1).
Figure 3 illustrates the neuroprotective effect of PNU-282987 in
the retina. (Figures 3A & 3B) represent typical confocal images of the
RGC layer obtained from the same animal and from the same retinal
location 4 mm from the ONH. (Figure 3A) was obtained from the
untreated retina. In the experimental eye of the same animal (Figure
1B), 1 mM PNU-282987 eye drops were applied before and after the
procedure to induce glaucoma-like conditions. One month following
the procedure to induce glaucoma, the animal was euthanized, both
retinas (treated and untreated) were removed and processed for RGC
staining with anti-Thy 1.1 antibody. Anti-Thy 1.1 labeled the plasma
membrane of RGC bodies (arrows) as well as bundled RGC axon
fascicles (double arrows). When the experimental eye was treated with
PNU-282987, there was no evidence of RGC loss typically associated
with the procedure to induce glaucoma-like conditions (Figure 3B).
In (Figure 3C & 3D), the procedure to induce glaucoma-like
conditions was performed on both eyes in the same Long Evans
rat. (Figure 3C) illustrates the effect of the procedure on anti-Thy
1.1 immunostained RGCs one month after the procedure. There
was a significant loss of RGC bodies from the RGC layer and the
bundles RGC axon fascicles (double arrows) begin to defasciculate
(arrow head) as axons in the bundle were lost [21]. (Figure 3D)
provides evidence that α7 nAChRs are responsible for PNU-282987’s
neuroprotective effect. The experimental eye that generated (Figure
3D) was intravitreally injected with 5 µl of 100 nM of the specific
α7 nAChR antagonist, MLA, before initiation of PNU-282987 eye
drops. In the presence of MLA, the neuroprotective effect of PNU28987 was eliminated. These results are summarized in (Figure 4).
1mM PNU-282987 prevented the loss of RGCs typically associated
with the procedure to induce glaucoma-like conditions. However, in
the presence of the MLA, neuroprotection due to PNU-282987 was
reduced in a dose dependent manner. The greatest effect of MLA
was demonstrated when 1 mM PNU-282987 eye drop treatments
were used after the procedure to induce glaucoma-like conditions
with hypertonic saline injections (Figure 4). However, an intravitreal
injection of 100 µl MLA into the vitreal chamber before hypertonic
saline injections significantly reduced the effect of each α7 nAChR
agonist (1 mM eye drop) to varying degrees. MLA was the most
effective in reducing PNU-282987’s neuroprotection (Figure 4),
followed by PHA-54316, SEN 12333, 3-bromocytisine, tropisetron,
DMAB and nicotine.

Discussion
In this study, evidence was provided that several α7 nAChR
agonists can be used in the Long Evans rat as a neuroprotective agent
against the loss of RGCs normally associated with glaucoma-like
conditions. Using a modified version of the Morrison model [24],
significant loss of RGCs occurred in an in vivo rat model after injection
of hypertonic saline solution into the episcleral vein of the animal’s
eye [20,21]. Four weeks after the procedure to induce glaucomalike conditions, RGCs decreased by an average of 28% compared to
Submit your Manuscript | www.austinpublishinggroup.com

Figure 4: MLA blocks neuroprotection of RGCs.
Each bar graph illustrated in figure 4 represents the average percent of RGC
change compared to internal controls from the same animal after different
treatment conditions including, 1) hypertonic saline injection (brown bar),
2) hypertonic saline injection with PNU-282987 treatment (grey bar) and
3) hypertonic saline injection with PNU-282987 treatment after intravitreal
injections of 3 different concentrations of MLA (yellow bars). Each bar graph
was generated from N’s of 4-20. The star represents significant difference
from the brown bar (hypertonic injection only). Error bars represent S.E.

untreated internal control RGC counts in the periphery of the retina.
This model was used to demonstrate the neuroprotective effect of
several α7 nAChR agonists in the retina when applied as eye drops.
Intravitreal injections are routinely used to treat retinal conditions
such as macular degeneration and macular edema [33-35], However,
these injections are invasive and certainly carry some risk. Many
stakeholders in drug development would concur topical delivery is
a more attractive route for chronic diseases such as glaucoma. As a
result, the various α7 nAChR agonists used in this study were applied
as eye drops. The main pathway for absorption of eye drops is typically
through the cornea. However, it is challenging to obtain therapeutic
drug tissue levels in the posterior segment using this route of delivery
[36,37].
Two different pieces of evidence support the conclusion that
topically applied α7 nAChR agonists used in this study reach
the retina: 1) intravitreal MLA blocked the effect of the topically
applied agents and 2) previous HPLC MS/MS studies from this lab
measured detectable levels of PNU-282987 in the retina after eye
drop application using the same treatment procedure as the current
study [21]. Treating the retina directly with eye drops has also been
used to analyze N-methyl-N-nitrosourea-induced photoreceptor
cell death [26], glaucomatous optic neuropathy [27] and to preserve
visual function at the retinal ganglion cell layer [25]. Once formulated
appropriately for long term use in humans, topical ophthalmic
therapy appears to be a non-invasive way to deliver α7 nAChR
agonists to the retina.
A growing body of evidence indicates that α7 nAChRs are
an attractive target for neuroprotection in the brain and retina.
J Ophthalmol & Vis Sci 1(1): id1003 (2016) - Page - 05
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Activation of α7 nAChRs in the brain have been linked to
neuroprotection against several neurodegenerative diseases [9,10].
There is strong evidence that α7 nAChRsreduce β-amyloid induced
toxicity in animal models of Alzheimer’s disease [11,12] and that the
α7 nAChRs plays a role in the pathophysiology of schizophrenia in the
brain of humans [13,14]. Previous in vitro studies using adult Long
Evans rats have demonstrated that, at certain concentrations, the α7
nAChR agonist, PNU-282987, eliminates RGC loss associated with
the procedure to induce glaucoma-like conditions [20,21]. As PNU282987 has adverse effects on a hERG anti target in the heart [23],
this comparison study was performed to assess the neuroprotective
effect of other α7 nAChR agonists, some of which may have a better
product safety profile.
PHA-543613 was found to have the largest neuroprotective
effect on RGC survival after the procedure to induce glaucoma-like
conditions. Like PNU-282987, 1 mM PHA-543613 eliminated the
loss of RGCs associated with the procedure. In fact, both PHA-543613
and PNU-282987 resulted in significantly more RGCs compared to
their internal controls when 1 mM was applied as eye drops. This
data suggests that neuroprotection of RGCs in a mammalian system
may be possible when relatively high concentrations of α7 nAChR
agonists are used.
PHA-543613 is a furo pyridine proved to be a potent, high affinity
agonist of alpha7 nAChRs under development for the therapeutic
treatment of cognitive disorders in people with schizophrenia and
Alzheimer’s disease [38,39]. PHA-543613 has been shown to be
active in relevant models in both in vitro and in vivo studies [38,39].
It demonstrates high oral bioavailability in rats and has a more
favorable hERG profile than PNU-282987 [39]. It rapidly penetrates
the blood brain barrier and shows effective auditory sensory gating
and objects recognition in an in vivo rat model [39], enhances the
neurovascular response in an Alzheimer’s mouse model to improve
recognition memory [40] and protects dopaminergic neurons in a rat
Parkinson’s model [41].
All of the other agents applied to adult Long Evans rat eyes
provided neuroprotection to a lesser degree than PHA-543613 and
PNU-282987. This inferiority is likely due to the less robust activity
at the target receptor as well as action of the agents at other receptors.
Tropisetron, 3-Bromocytisine, SEN 12333 and DMAB are classified
as partial α7 agonists with affinities for other types of receptors.
Tropisetron is a potent 5-HT3 antagonist and partial agonist of α7
nAChRs [42-44]. SEN 12333 has been found to be an α7 nAChR
agonist as well as an antagonist for H3 receptors and shows weak
agonist activity at α3 nAChRs [45,46]. 3-Bromocytisine is a nicotinic
agonist of many different functional ACh receptors including α4β4,
α4β2 and α7 nAChRs [47,48], while DMAB has been used as a partial
agonist at α7 nAChRs to improve learning and memory in rats but is
also an α4β2 antagonist [49-51].
The results using PHA-543613 and PNU-282987, as well as the
selective α7 nAChR antagonist, MLA, support the hypothesis that
activation of α7 nAChRs represents a path towards neuroprotection
in the retina. All currently available treatments for glaucoma
are currently focused on reducing IOP, the primary risk factor
associated with glaucoma [30-32]. These topical pharmaceutical
glaucoma therapies decrease the production of aqueous humor
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or alter outflow fluid dynamics. Surgical procedures are similarly
predominant technologies to enhance the drainage of aqueous
humor [52]. However, these treatments alone are insufficient to halt
the progression of blindness associated with glaucoma [53-55]. New
treatment approaches are needed to prevent the loss of RGCs in
glaucoma and α7 nAChR agonists may someday become an effective
intervention in this setting.
How could activation of α7 nAChRs in the retina induce
neuroprotection to prevent the loss of RGCs associated with glaucoma?
In previous studies using isolated porcine and rat RGCs, ELISA and
immunocytochemical studies have demonstrated that ACh activation
of α7 nAChRs triggered activation of the PI3→Akt→Bcl2 signaling
cascade to provide neuroprotection against glutamate induced
excitotoxicity [56,57]. These studies hypothesized that calcium
influx through ionotropic α7 nAChR channels was involved in
triggering the intracellular cascade to induce neuroprotection. Other
studies have demonstrated that the link between glutamate receptor
activation and signaling cascade initiation is calcium permeation
through glutamate channels [58,59]. It may be that permeation of
extracellular calcium through nAChR channels is the key to inducing
neuroprotective pathways in rat RGCs in glaucoma. In this scenario,
calcium permeation through α7 nAChRs triggers neuroprotective
signaling cascades or may induce neuroprotection through other
mechanisms, such as internalization of NMDA receptors [60].

Conclusion
The results from this paper demonstrate the neuroprotective effect
of several alpha7 nAChR agonists on RGC survival in a rat glaucoma
model. Each agonist provided neuroprotection in a dose dependent
manner although the largest neuroprotective effects were produced
when PHA-543613 and PNU-282987 were applied topically. The
results from this study have also provided evidence that eye drop
application of the agonists is sufficient to prevent loss of RGCs in
the Long Evans rat. These results support a scenario where future
therapies for neurodegenerative diseases of the CNS may involve,
either alone or in combination with other agents, the pharmacologic
activation of alpha7 nAChRs.
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